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pRB, the product of the retinoblastoma tumor suppressor 
gene, operates in the midst of the cell cycle clock appara- 
tus. Its main role is to act as a signal transducer connecting 
the cell cycle clock with the transcriptional machinery. In 
this role, pRB allows the clock to control the expression 
of banks of genes that mediate advance of the cell through 
a critical phase of its growth cycle. Loss of pRB function 
deprives the clock and thus the cell of an important mecha- 
nism for braking cell proliferation through modulation of 
gene expression. 
pRB and the G1 Restriction Point 
pRB exerts most and perhaps all of its effects in a defined 
window of time in the first two thirds of the G1 phase of 
the cell cycle. As demonstrated by Pardee almost two de- 
cades ago, this is the time window during which the mam- 
malian cell makes most of its decisions about growth ver- 
sus quiescence. Cells entering G1 from mitosis require 
serum mitogens continuously until several hours before 
the onset of S phase; thereafter, they become relatively 
serum independent. This transition from a serum-depen- 
dent to serum-independent s ate is demarcated by a dis- 
crete point in time, which he termed the R (restriction) 
point (Pardee, 1989). By passing through the R point, the 
cell commits itself to traverse the remainder of its growth 
cycle through M, barring major misadventure such as DNA 
damage or metabolic disturbance. Such a commitment 
decision represents a transition in the life of the cell that 
is as important as the much-studied G0/G1 emergence of 
the cell from quiescence. 
pRB undergoes a readily discernible alteration at a time 
close to and perhaps contemporaneous with the R point 
transition. Through the preceding hours of G 1, pRB is found 
in an underphosphorylated form. The bulk of pRB pre- 
pared from cells during the last several hours of G1 is, in 
contrast, hyperphosphorylated, pRB maintains this hyper- 
phosphorylated configuration throughout the remainder of 
the cell cycle, losing its multiple phosphate groups only 
upon emergence from M. 
Several lines of evidence indicate that this phosphoryla- 
tion causes the inactivation of the growth inhibitory func- 
tions of pRB. First, oncoproteins made by three classes 
of DNA tumor viruses eliminate pRB function by binding 
and sequestering hypophosphorylated pRB, ignoring hy- 
perphosphorylated forms. Second, the hypophosphory- 
lated form binds and ostensibly controls a number of other 
cellular proteins (see below); the hyperphosphorylated 
form appears to have lost the ability to interact with these 
proteins. Third, conditions that cause pRB phosphoryla- 
tion favor cell proliferation (reviewed by Cobrinik et al., 
1992). 
The schedule of pRB phosphorylation leads to a simple 
and attractive functional model that is still largely unproven. 
A cell that has proceeded through most of G1 encounters 
the R point gate held shut by its guardian, pRB. Should 
conditions be propitious for advance into the remainder 
of the cell cycle, pRB will undergo phosphorylation and 
attendant functional inactivation, causing it to open the 
gate and to permit the cell to proceed into late G1. Cells 
that lack pRB function for a variety of reasons will proceed 
blithely into late G1 without undergoing the control nor- 
mally imposed by pRB and, by extension, the upstream 
influences that regulate its phosphorylation. These up- 
stream influences include growth-promoting signals such 
as mitogens as well as growth inhibitory agents such as 
transforming rowth factor 13 (TG FI3) and contact inhibition. 
Having lost their pRB servant, these physiologic signals 
lose much of their voice in the decision of the cell to pass 
through the R point gate and proceed into late GI. 
This model raises two major questions. How precisely 
do such physiologic signals determine whether or not pRB 
undergoes phosphorylation and resulting inactivation? 
And how does pRB, for its part, prevent or allow advance 
of the cell into late GI? 
Control of pRB Phosphorylation 
Accumulating evidence indicates that components of the 
cell cycle clock mediate much and perhaps all pRB phos- 
phorylation. Phosphopeptide analysis of pRB suggests 
more than a dozen distinct sites of phosphorylation on 
either serine or threonine residues. This creates a puzzle: 
why are so many sites modified? Do they indicate that 
multiple kinases converge on pRB, using it as a substrate 
to integrate their various signals? 
The amino acid sequences surrounding the subset of 
pRB phosphorylation sites that have been analyzed in de- 
tail are typical of those modified by cyclin-dependent ki- 
nases (CDKs) (Lees et al., t 991). Thus, G1 cyclins, serving 
as regulatory subunits of their partner CDKs, are pre- 
sumed to direct these enzymes to the pRB substrate, re- 
sulting in its phosphoryiation. 
Cyclins of the D class (D1, D2, and D3) are most promi- 
nently implicated in the phosphorylation of pRB. These 
cyclins serve as regulators of the CDK4 and CDK6 ki- 
nases. Incubation of D cyclins with CDK4/CDK6 and a 
pRB fusion protein yields phosphorylation of pRB in vitro 
(Kato et al., 1993; Ewen et al., 1993a). Moreover, as de- 
scribed below, physiologic regulators that interfere with 
CDK4/CDK6 function also serve to block pRB phosphory- 
lation in vivo. These D cyclins are unique in their ability to 
form physical complexes with pRB; the precise functional 
significance of this interaction remains to be elucidated 
(Dowdy et al., 1993; Ewen et al., 1993a). 
A role for cycli n E in contributing to pRB phosphorylation 
is also strongly suggested. Ectopic expression of cyclin 
E in human osteosarcoma cells causes pRB phosphoryla- 
tion (Hinds et at., 1992). Moreover, in most cells, the levels 
of cyclin E mRNA and protein rise dramatically at the time 
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in mid-to-late G1 when pRB undergoes phosphorylation 
(Lew et al., 1991; Koff et al., 1991). pRB undergoes phos- 
phorylation in a normal fashion in DNA tumor virus-trans- 
formed cells; in these cells, viral oncoproteins occupy the 
site on pRB to which D cyclins normally bind (DeCaprio 
et al., 1989). This suggests that certain cyclin-CDK com- 
plexes that do not depend on cyclin D-pRB association 
can also participate in pRB phosphorylation in late GI. 
Taken together, these various lines of evidence converge 
on the notion that cyclin E-CDK2 complexes, like cyclin 
D-CDK4/CDK6 complexes, participate in pRB phosphory- 
lation. 
One line of experiments uggests that both classes of 
cyclins may be important. When ectopically expressed in 
Saccharomyces cerevisiae, pRB undergoes a phosphory- 
lation that is almost indistinguishable from its modification 
in mammalian cells. This phosphorylation requires multi- 
ple yeast G1 cyclins, CLN3 plus either CLN1 or CLN2. The 
loss of CLN3 function can be largely reversed by intro- 
duced mammalian cyclin D1 ;absence of CLN1/CLN2func- 
tion can be compensated by mammalian cyclin E (Hata- 
keyama et al., 1994). This hints at a similar collaboration 
operating in mammalian cells. 
The precise nature of the collaboration between the D 
cyclins and cyclin E in promoting pRB phosphorylation re- 
mains unclear. One simple model holds that cyclin D-CDK4/ 
CDK6 complexes initially create hyperphosphorylated 
pRB; an identical spectrum of phosphorylated residues 
on pRB is then maintained by subsequently activated 
cyclin E-CDK2 complexes. Alternatively, cyclin D-CDK4/ 
CDK6 complexes may modify pRB in a way that makes it 
into an attractive substrate for further, qualitatively distinct 
modification by cyclin E-CDK2. 
Effector Functions of pRB: Control 
of Transcription by E2F 
As demonstrated 4years ago, when pRB is hypophosphor- 
ylated, it is capable of binding to the E2F transcription 
factor; phosphorylation causes it to lose its grip on E2F, 
presumably enabling the latter to proceed with the activa- 
tion of a cohort of client genes whose transcription it con- 
trols (Chellappan et al., 1991). 
We now realize that the term E2F subsumes a group 
of at least five distinct, closely related transcription factors 
that are all targeted to variants of the consensus nucleo- 
tide sequence TTTCGCGC. This sequence is present in 
the promoters of a number of genes that are known or 
presumed to be important for cell growth control, including 
most notably c-myc, B-myb, cdc2, dihydrofolate reduc- 
tase, thymidine kinase, and the promoter of the E2F-1 gene 
itself (reviewed by Nevins, 1992; LaThangue, 1994). This 
generates the next level of model building: by reversibly 
sequestering E2Fs, pRB controls the expression of genes 
whose products are important participants in the cell cycle 
program. Thus, 
G1 cyclins:CDKs -~ pRB --I 
responder --, cell cycle 
genes advance 
E2Fs '-> 
Not unexpectedly, this scheme, though correct in out- 
line, has greater complexity in its details. Of the five known 
E2Fs, only three, E2F-1, E2F-2, and E2F-3, are known to 
be under the direct control of pRB; hypophosphorylated 
pRB appears to bind the other two only weakly. These 
outliers (E2F-4 and E2F-5) seem to be under the control 
of at least one of the cousins of pRB in the cell, p107. 
(The role of the other cousin, p130, remains to be re- 
ported.) p107 seems to have weaker affinities for E2F-1, 
E2F-2, and E2F-3 than does pRB (Ginsburg et al., 1994; 
Beijersbergen et al., 1994; Cao et al., 1992; Cobrinik et 
al., 1993; Dyson et al., 1993; Lees et al., 1993; Shirodkar 
et al., 1992). 
The possible existence of two parallel pathways 
pRB --i E2Fsl,2, and3 
p107, p130 --~ E2Fs4and5 
raises many questions. It is unclear whether all the E2Fs 
target a common constituency of responder genes or, al- 
ternatively, whether each is specialized to regulate its own 
private clientele of transcriptional promoters. There is also 
suggestive evidence that each of these E2Fs forms com- 
plexes with pRB and its cousins in defined periods of the 
cell cycle, hinting that each may be specialized to control 
genes in a defined period of G1 or S. Beyond this, the 
rationale for their multiplicity is unclear. 
The precise mechanisms by which pRB (and its cousins) 
regulate gene function may be more subtle than simple 
alternating cycles of sequestration and liberation of E2Fs. 
Gel retardation analyses indicate that complexes of pRB 
and E2Fs can bind to the consensus E2F target DNA se- 
quence in a number of promoters (Nevins, 1992; La- 
Thangue, 1994). This indicates that pRB binding does not 
preclude simultaneous association of an E2F with DNA. 
Thus, pRB (or its cousins) may act in situ at transcriptional 
promoters, using already bound E2Fs as docking sites. 
Indeed, much evidence suggests that pRB may actively 
repress transcription of promoters on which this complex 
is sitting. Hence, removal of an E2F-binding site may liber- 
ate a promoter from pRB-mediated transcriptional repres- 
sion (Weintraub et al., 1992; Lam and Watson, 1993; Dyn- 
lacht et al., 1994; Qin et al., 1995). 
Alternative Effector Pathways Regulated by pRB 
pRB may regulate a number of downstream effectors be- 
sides the much-studied E2Fs. pRB is a relatively abundant 
nuclear protein, being present in molar amounts that are 
as much as two orders of magnitude above the levels of 
the E2Fs. Accordingly, it has substantial capacity to con- 
trol the activities of yet other nuclear proteins. 
Genes encoding other pRB-binding proteins have been 
reported over the past several years. Included among 
these are the Elf-l, MyoD, PU. 1, ATF-2, and c-Abl proteins 
(reviewed by Wang et al., 1994). The effector functions of 
most of these remain unknown. Most intriguing of these 
is the nuclear tyrosine kinase encoded by the cellular abl 
proto-oncogene. Hypophosphorylated pRB is reported to 
bind directly to the active catalytic domain of the c-Abl 
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kinase, blocking its function. As expected, hyperphos- 
phorylated pRB loses this binding ability (Welch and 
Wang, 1993, 1995). By binding multiple effectors such as 
E2Fs and Abl, pRB may be able to modulate simultane- 
ously the activity of a number of downstream growth- 
controlling pathways. 
The various pRB-regulated downstream effector path- 
ways suggested by these associations would seem a priori 
to contribute equally to the ability of pRB to control cell 
proliferation. But two lines of evidence indicate that the 
initially discovered E2F-regulated pathway represents the 
pRB function of preeminent importance. Ectopic expres- 
sion of E2F-1 enables a cell to move from quiescence into 
S phase, thereby traversing the entirety of G1 (Johnson et 
al., 1993; Qin et al., 1994; Shan and Lee, 1994). Moreover, 
introduction of an E2F-1 expression plasmid into human 
osteosarcoma cells can override a pRB-imposed block of 
the growth of these cells (Qin et al., 1994). Taken together, 
these functional tests suggest that E2Fs are dominant de- 
terminants of G1 progression and may even be the only 
critical rate-limiting effectors of pRB action. 
One observation suggests that pRB and, by extension, 
the E2F transcription factors under its immediate control 
play a more central role in controlling cell cycle progres- 
sion than do its cousins p107, p130, and their respective 
effectors: many human tumor cell genomes have been 
found to have lost pRB function through chromosomal 
gene mutation, while acom parable loss of a p107 or a p130 
allele has never been reported (reviewed by Weinberg, 
1992). But this hardly proves the unique importance of 
pRB in cell cycle regulation. Equally weighty roles of p107 
and p130 may well be masked by a functional redundancy 
that they have with one another. Such redundancy would 
drastically reduce the likelihood of their being eliminated 
from tumor cell genomes during tumor progression. 
pRB as an Integrator of Positive Signals 
The evidence cited above indicates that the pRB trans- 
ducer sits at a critical node in the signaling circuitry of the 
cell, acting as a recipient of several afferent signals that 
converge on it and responding to these in turn by regulat- 
ing a number of downstream effector pathways such as 
those involving E2Fs and Abl. The richness and complex- 
ity of the afferent signaling pathways have only recently 
been appreciated. 
Physiologic signals that favor cell proliferation should 
encourage pRB phosphorylation. Most of these signals 
originate with mitogens that impinge on cell surface recep- 
tors and in turn activate cytoplasmic signal transduction 
pathways that convey growth stimulatory signals to the 
nucleus. These signals must then act in one way or another 
to stimulate the forward progress of the cell cycle clock. 
At present, the connections between these cytoplasmic 
mitogenic signaling pathways and the nuclear clock are 
poorly understood. 
One clear connection, however, is revealed by the be- 
havior of cyclin DI. As described above, it contributes 
importantly to pRB phosphorylation. Like the Myc protein, 
it turns over rapidly with a lifetime of about 15 min, and 
its steady-state levels rapidly decline upon removal of ex- 
tracellular mitogen (Matsushime et al., 1991 ; Sherr, 1993). 
This would suggest that at the time in mid-to-late G1 when 
the cell is anticipating pRB phosphorylation, the cell cycle 
clock can gauge the extracellular mitogen environment 
by determining the level of cyclin DI. Levels of cyclin D 
above a certain threshold will thus favor pRB phosphoryla- 
tion; subthreshold levels will make this step difficult. 
The activity of the CDK enzymes is controlled both by 
their association with cyclins and by phosphorylation of 
the CDK polypeptide itself. For example, CDK2 is phos- 
phorylated on threonine residue 160, a modification that 
is essential for its catalytic activity (Desai et al., 1992; Solo- 
mon et al., 1992). These phosphorylations are mediated by 
an enzyme complex termed CDK-activating kinase (CAK), 
which itself is composed of a CDK (termed variously MO15 
or CDK7) and a cyclin (cyclin H) (Fisher and Morgan, 1994; 
M&kal& et al., 1994). Since CDK7 is also dependent upon 
an activating phosphorylation event by yet another kinase, 
this suggests the possibility of positive control by an ex- 
tended kinase cascade, a notion that at present lacks di- 
rect experimental support. 
Mitogens must also encourage in some fashion the mid- 
to-late induction of cyclin E mRNA and the increase in 
cyclin E protein. How mitogenic signals converge on cyclin 
E activation and in turn on the phosphorylation of pRB is 
also poorly understood at present. 
pRB as an Integrator of Negative Signals 
We now know that a variety of physiologic growth inhibitory 
signals prevent pRB phosphorylation and in this way block 
advance of the cell through the R point and into late G1 
(reviewed by Wang et al., 1994). These growth inhibitory 
mechanisms do not seem to impinge on pRB directly but 
operate instead by modulating the activities of the CDKs 
that are responsible for pRB phosphorylation. To date, 
three well-studied physiologic signals have been shown 
to block pRB phosphorylation in this manner. These are 
TGFI3, cyclic AMP (cAMP), and contact inhibition. In each 
instance, a negative growth signals mobilizes a CDK inhib- 
itor (CDKI) protein that associates either with a CDK or 
with a cyclin-CDK complex and blocks its function. 
At least three molecular mechanisms have been pro- 
posed to explain the ability of TGFI~ to obstruct pRB phos- 
phorylation. The first of these involves p27 ~pl, a CDKI that 
interacts with CDK2, CDK4, and CDK6 and prevents their 
functional activation at the hands of CAK (Polyak et al., 
1994; Slingerland et al., 1994; Toyoshima and Hunter, 
1994). While levels of p27 ~pl are not affected by TGF~ 
treatment, the CDK2 of TGF~-treated cells has been found 
to be associated with p27 ~p~, suggesting some type of 
posttranslational regulation of its activity (Ewen et al., 
1993b; Polyak et al., 1994). 
An alternative mechanism is suggested by the recent 
discovery that TGF~ can induce expression of p15 jNK4B, 
another CDKI, by as much as a factor of 30. p15 targets 
CDK4/CDK6, competing with D cyclins for binding to 
CDK4/CDK6 (Hannon and Beach, 1994). Recent reports 
provide evidence that p15 (and its close cousin, p16 jNK4A) 
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can only inhibit cell proliferation in cells possessing func- 
tional pRB (Guan et al., 1994; Serrano et al., 1995). If 
extended and solidified, this would indicate that the only 
physiologically important target of cyclin D-CDK4/CDK6 is 
pRB and, hence, that this TGFI3 ~p15-JCDK4/CDK6 path- 
way has pRB as its sole end point. 
TGFI3 also acts to reduce dramatically the levels of 
CDK4 in certain responsive cell types (Ewen et al., 1993b). 
This is also an effective means of preventing pRB phos- 
phorylation in that, as mentioned above, the cyclin D-CDK4/ 
CDK6 complexes play a critical role in the phosphorylation 
of pRB. The TGFI3-induced decrease in CDK4 levels may 
result in the liberation of substantial amounts of p27 Kips, 
which in turn may proceed to antagonize the functioning 
of yet other CDKs in the cell. Contact inhibition and cAMP 
also appear to act through their ability to mobilize p27 Kip1 
(Polyak et al., 1994; Kato et al., 1994). The end results of 
these various growth inhibitory mechanisms are the same: 
they all converge on pRB, blocking its phosphorylation 
and preventing opening of the R point gate. 
Radiation and other DNA-damaging agents also block 
pRB phosphorylation through use of another CDKI, 
termed variously p21, Wafl, and Cipl (EI-Deiry et al., 
1993; Harper et al., 1993; Dulic et al., 1994). The physio- 
logic rationale here is simple: should the cell sustain ge- 
netic damage while it is in G2, M, or much of G1, a pRB- 
imposed cell cycle block in G1 will enable the DNA repair 
apparatus to go about its work of restoring genomic integ- 
rity without the threat of imminent advance of replication 
forks and resulting inadvertent replication of unrepaired 
DNA sequences. Once DNA lesions are erased, then the 
pRB-imposed block may be lifted and the cell permitted 
to advance into S and replicate its now-restored genome. 
Alternatively, in the face of irreparable lesions, the cell 
may choose to commit itself to an apoptotic death. 
p53 acts as an intermediary here. Normally a highly un- 
stable protein with a lifetime of 15 min or so, its steady- 
state levels increase rapidly upon DNA damage, p53 in 
turn activates expression of the p21 CDKI, and p21 then 
blocks the activity of both CDK2 and CDK4/CDK6 (Kastan 
et al., 1991 ; Hall et al., 1993). As with the other antiprolifer- 
ative signals, this mechanism prevents phosphorylation 
of pRB and passage through the R point gate. 
pRB and Regulation of the Clock 
The interplay of cyclins, CDKs, CDKIs, and pRB enables 
the cell cycle clock to control its own forward progress. 
At least two types of regulatory circuits utilizing these clock 
components have been proposed to date. Others will 
surely follow. 
The first of these has been suggested to operate in mid- 
G1, serving as a timing device that triggers activation of 
cyclin D-CDK4/CDK6 and the subsequent R point transi- 
tion 6-10 hr after the onset of G1 (Kato et al., 1994). This 
model postulates that p27 ~p~ CDKI is expressed at rather 
constant levels throughout GI. Early in G1, any cyclin 
D-CDK4/CDK6 that is present will associate with and be 
inactivated by p27 ~p~, which is initially present in molar 
excess and acts as a stoichiometric inhibitor of cyclin 
D-CDK4/CDK6 activation. The levels of cyclin D-CDK4/ 
CDK6 will increase gradually as cells progress through 
mid-G1. Eventually, cyclin D-CDK4/CDK6 levels will ex- 
ceed a threshold beyond which they out-titer the limited 
amount of p27 Kjp~ that is present. These excess cyclin 
D-CDK4/CDK6 complexes can now be phosphorylated 
by CAK and, thus empowered, can initiate pRB phosphory- 
lation and trigger the R point transition. 
The second of these proposed regulatory circuits in- 
volves pl 6 jN~4, the CDKI that operates to bind CDK4/CDK6 
and to preempt their association with D cyclins. Some of 
its discoverers noted that p16 is overexpressed in cells 
that have been transformed by DNA tumor viruses and 
thus carry a sequestered, inactive pRB (Serrano et al., 
1993). Others have found that pRB acts to regulate nega- 
tively the promoter of the p16 gene (Li et al., 1994). More- 
over, p16 expression increases strongly toward the end 
of G1 after pRB undergoes inactivation through phosphor- 
ylation (Tam et al., 1994). pRB thus seems to antagonize 
p16 expression. 
These observations, taken together, suggest the opera- 
tion of a negative feedback loop which operates as follows. 
First, cyclin D, operating together with a partner CDK4/ 
CDK6, triggers pRB phosphorylation as described above. 
Second, pRB, now functionally inactivated, releases a 
transcription factor that causes induction of p16 expres- 
sion. Third, pl 6 proceeds to bind all CDK4/CDK6, evicting 
cyclin D from its CDK4/CDK6 association. Fourth, cyclin 
D, no longer protected by association with its CDK4/CDK6 
partner, is degraded, resulting in termination of its activi- 
ties toward the end of G1. (Tam et al., 1994). This mecha- 
nism would serve to limit the participation of cyclin D in 
cell cycle regulation to a defined window of time that be- 
gins just before the R point transition and ends at the G IIS 
transition. 
These mechanisms may help to solve an intriguing puz- 
zle. Some have noted that human tumor cells that lack 
pRB express CDK4/CDK6 but do not show cyclin D-CDK4/ 
CDK6 complexes (Bates et al., 1994). These tumor cells 
have now been found to express high levels of pl 6, which, 
by binding to CDK4/CDK6, blocks D cyclins from complex- 
ing with these CDKs, resulting in the apparent degradation 
of the uncomplexed cyclins (Parry et al., 1995). 
pRB and Cancer 
A diverse body of evidence now indicates that pRB stands 
in the midst of a regulatory pathway that suffers disruption 
during the pathogenesis of very many human tumors. In- 
deed, it is possible that this pathway may one day be found 
to be deregulated in all human malignancies. To reprise 
the above discussions: 
p15/16 --J CDK4: cyclin D 
HPV E7 
I-- 
--I pRB --I 
T 
CDK2: cyclin E 
E2Fs 
In retinoblastomas, in small cell lung carcinomas, and 
in many sarcomas and bladder carcinomas, pRB function 
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is lost through mutations of the pRB gene (Horowitz et al., 
1990). In the great majority of cervical carcinomas, this 
end is achieved through the actions of the human papillo- 
mavirus E7 oncoprotein (Dyson et al., 1989; zur Hausen, 
1991). In many esophageal, breast, and squamous cell 
carcinomas, the cyclin D gene is amplified (Jiang et al., 
1992; Lammie et al., 1991); cyclin D1 overexpression is 
achieved in B cell lymphomasthrough chromosomal trans- 
location (Motokura et al., 1991 ). Herpesvirus saimiri, a po- 
tently oncogenic virus in certain primate hosts, causes 
expression of its own virus-encoded D-type cyclin (Jung 
et al., 1994). The CDK4 gene is amplified in many glioblas- 
tomas and some gliomas (He et al., 1994; Schmidt et al., 
1994). p15, pl 6, or both may be deleted in many esopha- 
geal squamous cell carcinomas, glioblastomas, lung, 
bladder, and pancreatic carcinomas (Schmidt et al., 1994; 
Kamb et al., 1994a; Nobori et al., 1994; Mori et al., 1994; 
Caldas et al., 1994; Zhou et al., 1994; Jen et al., 1994) or 
may be present in mutant form in the germline of families 
with familial melanoma (Hussussian et al., 1994; Kamb et 
al., 1994b). 
The centrality of this control pathway and the importance 
of its deregulation during tumor progression are further 
highlighted by a study of 55 small cell lung carcinomas. 
Of these, 48 lacked normal pRB expression but showed 
the wild-type p16 ~NK4 gene product; six of the remaining 
seven tumors lacked p16 ~NK4 protein but expressed pRB 
at normal levels (Otterson et al., 1994). 
The various changes catalogued above all converge on 
the same end point of depriving the cell of the services 
of pRB, either through its functional inactivation (via se- 
questration or deregulated phosphorylation) or through its 
genetic inactivation (via chromosomal mutation). As a di- 
rect consequence, E2Fs are liberated from pRB control 
and the progression of cells into late G1 and S becomes 
unconstrained. 
pRB and Cell Biology 
The logic of the nuclear circuitry governing pRB phosphor- 
ylation, as described above, provides little insight into the 
role of pRB and the R point transition in normal cell physiol- 
ogy. As described earlier, pRB implements the decision 
by the cell to pass through this checkpoint in mid-to-late 
GI. When pRB fails to undergo phosphorylation, the prog- 
ress of the cell through its active growth cycle is blocked 
at this point. 
The subsequent fate of the cell is unclear, however, if 
only because several alternative fates exist. Most obvious 
is a return by the cell to GO, from which it may reemerge 
on some future occasion. Recently acquired evidence indi- 
cates that a pRB-imposed block on cell cycle progression 
may be a prerequisite for other, less reversible types of exit 
from the cell cycle leading to differentiation or senescence. 
Our current understanding of the connections between 
the R point blockade and the decisions governing the long- 
term fate of the cell is rudimentary. Importantly, any at- 
tempts at ascribing critical roles to pRB and the R point 
must be tempered by the results obtained from targeted 
inactivation of the Rb gene in the mouse germline. Homo- 
zygous mutant embryos are essentially normal until day 
12-13 of gestation, when they die with defects in both 
hepatic erythropoiesis and neuronal development (Clarke 
et al., 1992; Donehower et al., 1992; Jacks et al., 1992; 
Lee et al., 1994). By this time, the vast majority of morpho- 
genetic decisions have already been made properly. They 
have occurred in the absence of pRB, a protein that is 
expressed widely and is purportedly controlling the prolif- 
eration of all cells in the developing embryo. 
Standing in apparent opposition to these in vivo observa- 
tions are several lines of evidence indicating that pRB 
plays an important role in the differentiation of a variety 
of cell types. For example, pRB levels strongly increase 
upon differentiation of basal keratinocytes and colonic 
crypt cells (Szekely et al., 1992). Moreover, in one in vitro 
model, CDK4, whose only substrate of consequence ap- 
pears to be pRB (see above), strongly decreases upon 
induced differentiation of murine erythroleukemia cells. 
This loss of CDK4 would deprive the cell of its means of 
initiating pRB phosphorylation and, indeed, an accumula- 
tion of hypophosphorylated pRB is observed in these cells 
as they differentiate. This differentiation is prevented in 
cells engineered to express CDK4 constitutively (Kiyo- 
kawa et al., 1994). Hence, stopping these cells in mid-to- 
late G1 appears to be a prerequisite to their subsequent 
egress from the cell cycle into a more differentiated state. 
Another in vitro model involves myeloid stem cells that 
can be induced to differentiate into neutrophils. Here, 
down-regulation of D cyclins and CDK4 ceases as cell 
enter into a state of differentiation. Ectopic, constitutive 
expression of cyclins D2 and D3 prevents this differentia- 
tion (Kato et al., 1993). As before, the prevention of pRB 
phosphorylation and the resulting proliferation block im- 
posed by pRB appear to be essential for subsequent cell 
differentiation. 
The body appears to have developed mechanisms to 
protect itself from the chaos that ensues when cells are 
called upon to differentiate but are unable to respond ap- 
propriately because they lack functional pRB (Lee et al., 
1994). Without such functional pRB, certain cell types are 
susceptible to apoptosis. This apoptosis depends upon 
the p53 protein (Morgenbesser et al., 1994) and represents 
a means by which tissues can eliminate individual cells 
that have lost pRB function. Such a protective mechanism 
also has implications for the process of cell transformation. 
In particular, cell clones that have lost pRB may survive 
and gain further advantage through the subsequent loss 
of p53 function. This may explain why a variety of DNA 
tumor viruses (papovaviruses, adenoviruses) have evolved 
the capability of simultaneously inactivating both of these 
tumor suppressor proteins. Moreover, it may explain why 
certain neuronal tissues in Rb- mice undergo apoptosis 
during development (Jacks et al., 1992). 
pRB also plays an important role in the process of cell 
senescence. While initially discovered as a phenomenon 
of cells grown in culture (Hayflick, 1965), it appears in- 
creasingly likely that senescence represents an antineo- 
plastic mechanism designed to limit the proliferative po- 
tential of cell clones in the body. Studies of senescence 
as it occurs in vitro indicate that it can be partially circum- 
vented by viral oncoproteins that inactivate pRB (Shay et 
Cell 
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al., 1991). By extension, one presumes that in vivo the 
loss of functional pRB through a variety of mechanisms 
permits evolving cell clones to gain replicative advantage 
and eventually to undergo immortalization. 
These observations only hint at the possible roles of 
pRB in normal cell physiology. Unfortunately, they have 
provided little help in resolving the major paradoxes sur- 
rounding pRB. How can most of mouse development pro- 
ceed in an essentially normal fashion in its absence? Why 
does pRB loss in humans lead specifically to the unusual 
retinal tumors and not to malignancies in the other tissues 
of young children? Why do humans, unlike all other mam- 
mals, suffer these eye tumors upon pRB loss? We may 
need to wait a long time before the answers are forth- 
coming. 
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